AMRI, Proteros ink new partnership

AMRI (Nasdaq: AMRI) and Proteros Biostructures GmbH (Proteros) announced today that they have signed an agreement for a joint offering to the life sciences industry. Proteros, an expert in the field of protein crystallization and X-ray structural analysis, provides services that complement AMRI's existing drug discovery capabilities in chemistry, in vitro biology, drug metabolism and pharmacokinetics services.

“We are excited about this new relationship that expands the depth and level of service we can offer to customers around the globe looking for integrated solutions from one point of service and contact”

Proteros' expertise in structural biology services combined with AMRI's expansive discovery and development capabilities provides biotechnology and pharmaceutical companies throughout the world access to a portfolio of contract services from two companies known for their high level of expertise, dedication to quality and impressive track record of success.

Torsten Neuefeind, Proteros CEO stated, "Proteros is pleased to announce this partnership and looks forward to the new opportunities we can provide to the life science community as a result of this alliance with AMRI."

"We are excited about this new relationship that expands the depth and level of service we can offer to customers around the globe looking for integrated solutions from one point of service and contact," said Thomas E. D'Ambra, Ph.D., AMRI Chairman, President and CEO.

Source Albany Molecular Research and Proteros Biostructures